The COVID-19 cardiovascular legacy: long COVID and its complications

This site is intended for UK healthcare professionals

The COVID-19 cardiovascular legacy: long COVID and its complications

30 April 2024

COVID-19, and specifically long COVID, is associated with an increased risk of cardiovascular disease. Listen as Professor Banerjee describes his work in this area, especially the STIMULATE-ICP trial, which looks at long COVID’s physiological and social impact. Find out about what the NHS is doing to tackle COVID-19 and its associated cardiovascular and metabolic abnormalities.

Speakers

Amitava Banerjee, Professor of Clinical Data Science, University College London, and Honorary Consultant Cardiologist, UCLH and Barts Health NHS Trust

Learning objectives

Learn how cardiovascular disease is both a risk factor and an outcome of the COVID-19 infection.
Know the evidence behind multi-organ and metabolic damage in long COVID, as well as the prevention of long COVID.
Understand the clinical trials that have successfully incorporated a learning health system approach to improve the recovery of people living with long COVID.